Fatty Liver ; metabolism ; Glucose ; metabolism ; Humans ; Hyperglycemia ; metabolism ; Lipoproteins ; metabolism ; Metabolic Syndrome ; metabolism

Alcohol Drinking ; adverse effects ; Humans ; Liver Diseases, Alcoholic ; therapy

Objective To evaluate the efficacy and safety of Adefovir dipivoxil in the 52-week treatment of chronic hepatitis B in China.Methods We randomly assigned 480 patients with chronic hepatitis B who were positive for hepatitis B e antigen(HBeAg)in China.During the first 12-week period,480 patients were randomly to receive either 10 mg of adefovir dipivoxil(ADV)or placebo once daily in a 2:1 ratio and in the second period,all patients were accepted ADV for 18 weeks.In the last 12-week stage,all patients treated by ADV were randomly to receive either 10 mg of ADV or placebo in a 2:1 ratio and patients treated by placebo were accepted ADV.The primary end point was serum HBV DNA change during the treatment.The secondary endpoints were ALT normalization rate,HBeAg loss rate and HBeAg seroconversion rate.Results At week 12,median serum hepatitis B virus(HBV)DNA levels of group AAA(ADV-ADV-ADV)and group AAP(ADV-ADV-Placebo) were reduced 3.4 and 3.3 log copies per milliliter,significantly greater than group PAA(Placebo- ADV-ADV)of 0.1 log copies/ml reduction(P

0.05). Conclusion The elimination half-life of magnesium isoglycyrrhizinate in patients with chronic hepatic impairment is 27 h,and the regiment of 100 mg once a day is recommended.

Fatty Liver ; diagnosis ; etiology ; therapy ; Humans

Adenine ; analogs & derivatives ; pharmacokinetics ; therapeutic use ; toxicity ; Antiviral Agents ; therapeutic use ; Clinical Trials as Topic ; Hepatitis B ; drug therapy ; Humans ; Organophosphonates

OBJECTIVETo study the effect of Chinese herbal compound (CHC) on the expression of hepatocyte cytochrome P450IIE1 in rat model of alcoholic fatty liver (AFL).

METHODSThe AFL rats models were established by administering the drinking water with 40%(v/v) ethanol, and the changes of pathology in liver and hepatocyte P450IIE1 expression, as well as the contents of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), vitamin E (VitE) in liver were detected and compared with those in the control group.

RESULTSFatty degeneration in liver recovered normally in the CHC-treated group. Immunohistochemical and in situ hybridization examination showed that CHC could inhibit the hepatocyte cytochrome P450IIE1 expression markedly, and restore the contents of MDA, SOD, GSH, VitE to nearly normal range.

CONCLUSIONCHC can prevent AFL through inhibiting the hepatocyte cytochrome P450IIE1 expression markedly

Animals ; Cytochrome P-450 CYP2E1 ; metabolism ; Drugs, Chinese Herbal ; pharmacology ; Fatty Liver, Alcoholic ; pathology ; Gene Expression ; Hepatocytes ; drug effects ; enzymology ; Immunohistochemistry ; Rats ; Rats, Sprague-Dawley

Fatty Liver ; metabolism ; prevention & control ; therapy ; Humans ; Insulin Resistance

Fatty Liver ; etiology ; pathology ; Humans ; Liver Cirrhosis ; etiology ; pathology ; Obesity ; complications ; pathology ; therapy ; Risk Factors

Biomarkers ; blood ; Humans ; Liver Cirrhosis ; blood ; diagnosis